Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Bionomics Ltd (BNOEF)

Bionomics Ltd (BNOEF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 81,689
  • Shares Outstanding, K 544,590
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta 2.17
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade BNOEF with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1400 +4.36%
on 04/14/21
0.1879 -22.25%
on 03/22/21
-0.0199 (-11.99%)
since 03/19/21
3-Month
0.1040 +40.48%
on 01/28/21
0.3500 -58.26%
on 02/26/21
+0.0296 (+25.41%)
since 01/20/21
52-Week
0.0240 +508.75%
on 05/04/20
0.3500 -58.26%
on 02/26/21
+0.1041 (+247.86%)
since 04/16/20

Most Recent Stories

More News
Novamind Increases Strategic Investment in Bionomics

Investment supports phase IIb clinical trial examining novel PTSD treatment

BNOEF : 0.1461 (-2.60%)
NM.CN : 1.240 (+5.98%)
NVMDF : 0.9100 (-4.72%)
Bionomics Successfully Completes A$22.9 million Equity Raise

, /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB:BNOEF) () has completed its 1 for 6 pro rata non–renounceable entitlement offer that was announced on () and concurrent placement that was announced...

BNOEF : 0.1461 (-2.60%)
Positive BNC210 7-Day Dosing Pharmacokinetic Study Exceeds Blood Exposure Projected for Phase 2b PTSD Trial

The 7-day dosing PK study in ten healthy volunteers (females and males) demonstrated that at a dose of 900 mg given twice daily, the tablet formulation of BNC210 had steady-state 12-hourly exposure levels...

BNOEF : 0.1461 (-2.60%)
Joint feasibility assessment of Bionomics' BNC210 and EmpathBio's MDMA derivative EMP-01 treatment regimen for PTSD

, /PRNewswire/ --Bionomics Limited (ASX: BNO, OTCQB: BNOEF, : AU000000BNO5) () today announced that it has entered into a Memorandum of Understanding with EmpathBio Inc (, a wholly owned subsidiary of...

BNOEF : 0.1461 (-2.60%)
BNO : 16.76 (-1.00%)
Novamind Announces Strategic Investment in Bionomics to Support PTSD Clinical Trial

Cedar Clinical Research to be Evaluated to Support Phase IIb Trial of Novel PTSD Treatment

NM.CN : 1.240 (+5.98%)
BNO : 16.76 (-1.00%)
BNOEF : 0.1461 (-2.60%)
$16 Million Capital Raise to Progress Bionomics BNC210 PTSD Trial

The new shares will be issued at per share representing a 263% premium to the Company's capital raise in and a 20% discount to the 30-day volume weighted average price (VWAP) as of . Completion of the...

BNOEF : 0.1461 (-2.60%)
Post-Traumatic Stress Disorder (PTSD) Therapeutics Market 2020-2024- Featuring AstraZeneca Plc, Bionomics Ltd., Among Others to Contribute to the Market Growth

The post-traumatic stress disorder (PTSD) therapeutics market is poised to grow by USD 909.86 mn during 2020-2024, progressing at a CAGR of over 9% during the forecast period.

AZN : 52.27 (+1.24%)
BNOEF : 0.1461 (-2.60%)
Recapitalisation Led by Sophisticated Life Sciences Investor - Apeiron Investment Group Ltd

Bionomics Limited (ASX: BNO, OTCQB:BNOEF) (Bionomics or Company), a clinical stage biopharmaceutical company, today announced that it has entered into a Subscription Agreement, with Apeiron Investment...

BNOEF : 0.1461 (-2.60%)
BNO : 16.76 (-1.00%)
Bionomics and MSD Scientists Publish Preclinical Findings for BNC375 in Peer-Reviewed Journal

Bionomics Limited (ASX: BNO, OTCQB:BNOEF), a global, clinical stage biopharmaceutical company, today announced that a paper describing the pharmacology of BNC375, a novel positive allosteric modulator...

BNOEF : 0.1461 (-2.60%)
BNO : 16.76 (-1.00%)
Sale of Bionomics' French Subsidiaries to Domain Therapeutics

Bionomics Limited (ASX:BNO, OTCQB:BNOEF), a global, clinical stage biopharmaceutical company leveraging proprietary platform technologies to discover and develop a deep pipeline of novel drug candidates...

BNOEF : 0.1461 (-2.60%)
BNO : 16.76 (-1.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Key Turning Points

3rd Resistance Point 0.1717
2nd Resistance Point 0.1653
1st Resistance Point 0.1577
Last Price 0.1461
1st Support Level 0.1437
2nd Support Level 0.1373
3rd Support Level 0.1297

See More

52-Week High 0.3500
Fibonacci 61.8% 0.2255
Fibonacci 50% 0.1870
Fibonacci 38.2% 0.1485
Last Price 0.1461
52-Week Low 0.0240

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar